Corporate | 4 June 2012 12:57
|
STADA Arzneimittel AG / Key word(s): Miscellaneous
Corporate News STADA sales companies once again successful in tenders for discount agreements in the German generics market – very good results in the second Barmer GEK tender round Bad Vilbel, June 4, 2012 – The STADA sales companies STADApharm GmbH, ALIUD PHARMA GmbH and cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH were very successful in the second round of tenders of Barmer GEK for discount agreements pursuant to Section 130 a SGB V valid throughout Germany. In the framework of this most recent Barmer GEK round with a total tender volume of approximately Euro 408 million, the three STADA sales companies were able to conclude contracts for a total of 13 active ingredients with Barmer GEK, the second largest German public health insurance organization, in which about 8.5 million of the patients covered by state insurance in Germany are members.
Nine of the active ingredients awarded are thereby accounted for by STADApharm, three active ingredients by ALIUD PHARMA and one active ingredient by cell pharm. The contracts are legally effective, start on August 1, 2012 and have a regular term of two years. Each respective STADA sales company acts as the single contract partner (single source) for the individual awards.
In light of all the discount agreements signed over recent months, among others in the context of the recent 8th AOK tender round, the STADA Executive Board continues to expect that the Group’s market share by volume in the German market will increase further. STADA’s market share by volume in the first quarter of 2012 amounted to approximately 13.4 percent and was thus one percent above the corresponding period of the previous year of approximately 12.4 percent.
Additional information:
End of Corporate News 04.06.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | STADA Arzneimittel AG | |
| Stadastraße 2-18 | ||
| 61118 Bad Vilbel | ||
| Germany | ||
| Phone: | +49 (0)6101 603- 113 | |
| Fax: | +49 (0)6101 603- 506 | |
| E-mail: | communications@stada.de | |
| Internet: | www.stada.de | |
| ISIN: | DE0007251803, DE0007251845, | |
| WKN: | 725180, 725184, | |
| Indices: | MDAX | |
| Listed: | Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 172727 04.06.2012 |